Comment on CMS-2026-1255-0001

Summary: Boehringer Ingelheim USA Corporation supports the proposed rule to increase transparency and reporting around prior authorization (PA) and utilization management practices. The company advocates for expanded reporting requirements, including per-drug data, "time to therapy" metrics, and protections for continuity of care to ensure patients have timely access to necessary medications.